CVM Company Profile and Key Details
AMEX : CVM
CEL-SCI
$3.53
0.11+3.22%
At Close 4:00 PM66.25
BESG ScoreESG Rating
Price Chart
Stock Price Today
CEL-SCI Corporation (CVM) stock surged +3.22%, trading at $3.53 on AMEX, up from the previous close of $3.42. The stock opened at $3.50, fluctuating between $3.41 and $3.66 in the recent session.
Stock Snapshot
3.42
Prev. Close
24.26M
Market Cap
3.41
Day Low
-0.95
P/E Ratio
-3.7
EPS (TTM)
-0.48
Cash Flow per Share
3.5
Open
6.87M
Number of Shares
3.66
Day High
91.82%
Free Float in %
0.26
Book Value
29.92K
Volume
Relevant Articles
SEC Fillings
Current Report (8-k)
| Filing Date | Accepted Date | |
|---|---|---|
Annual Report (10-k)
| Filing Date | Accepted Date | |
|---|---|---|
Stock Price History Chart
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Mar 25, 2026 | 3.50 | 3.66 | 3.41 | 3.53 | 29.92K |
| Mar 24, 2026 | 3.45 | 3.70 | 3.42 | 3.42 | 30.89K |
| Mar 23, 2026 | 3.56 | 3.57 | 3.31 | 3.48 | 39.91K |
| Mar 20, 2026 | 3.71 | 3.73 | 3.44 | 3.44 | 33.1K |
| Mar 19, 2026 | 3.52 | 3.88 | 3.52 | 3.66 | 16.35K |
| Mar 18, 2026 | 3.70 | 3.82 | 3.57 | 3.72 | 35.17K |
| Mar 17, 2026 | 3.53 | 3.82 | 3.53 | 3.60 | 24.17K |
| Mar 16, 2026 | 3.67 | 3.74 | 3.46 | 3.53 | 27.22K |
| Mar 13, 2026 | 3.72 | 3.72 | 3.45 | 3.57 | 41.59K |
| Mar 12, 2026 | 3.65 | 3.96 | 3.52 | 3.52 | 18.42K |
| Mar 11, 2026 | 3.73 | 3.85 | 3.60 | 3.70 | 14.61K |
| Mar 10, 2026 | 3.89 | 3.93 | 3.69 | 3.70 | 17.35K |
| Mar 09, 2026 | 3.82 | 3.99 | 3.82 | 3.87 | 20.29K |
| Mar 06, 2026 | 3.88 | 4.12 | 3.67 | 3.94 | 63.79K |
| Mar 03, 2026 | 3.78 | 3.78 | 3.45 | 3.55 | 53.2K |
| Mar 02, 2026 | 4.17 | 4.17 | 3.67 | 3.83 | 95.26K |
| Feb 27, 2026 | 4.69 | 4.70 | 4.10 | 4.26 | 107.41K |
| Feb 26, 2026 | 4.42 | 4.68 | 4.32 | 4.56 | 33.68K |
| Feb 25, 2026 | 4.61 | 4.65 | 4.35 | 4.39 | 32.23K |
| Feb 24, 2026 | 4.42 | 4.71 | 4.36 | 4.58 | 42.14K |
Contact Details
About Company
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was incorporated in 1983 and is headquartered in Vienna, Virginia.
Company Information
| Employees | 43 |
| Beta | 0.91 |
| Sales or Revenue | $0.00 |
| 5Y Sales Change% | -1% |
| Fiscal Year Ends | September |
| Sector | Healthcare |
| Industry | Biotechnology |
Stock Peers
TBXU
00
Direxion Daily Biotech Top 5 Bull 2X ETF$29.80PTN1.15+5.79%
Palatin Technologies, Inc.$21.00PTHS-1.41-6.41%
Pelthos Therapeutics Inc.$20.59AGE-1.5-11.90%
AgeX Therapeutics, Inc.$11.10ARMP0.4+4.87%
Armata Pharmaceuticals, Inc.$8.61CYBN0.1+1.22%
Cybin Inc.$8.28NRXS0.46+6.52%
NeurAxis, Inc.$7.51PHGE0.03+0.62%
BiomX Inc.$4.89CANF0.1+3.19%
Can-Fite BioPharma Ltd.$3.23SER0.6+24.69%
Serina Therapeutics, Inc.$3.03Company Overview
CEL-SCI Corporation (AMEX:CVM) closed at $3.53 USD, gaining $0.11 (3.22%) from the previous close of $3.42. The stock is currently mid-range between its 52-week high and low $1.98 and $13.48. With a market capitalization of about $24.26 million, CEL-SCI Corporation is classified as a micro-cap and shows market-like volatility (beta ~0.91). Key stats such as the average daily volume over the past year has been around 57.50 thousand shares, volume is running light vs its 52-week average. Headquartered in Vienna, VA, CEL-SCI Corporation operates in the Healthcare sector and the Biotechnology industry. Led by CEO Geert R. Kersten, the company employs approximately 43 people and listed since December 08, 1983. CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases.
Technical Performance
CVM has shown mixed momentum, gaining 2.34% over the past week and -40.68% over the past quarter, though year-to-date performance is down -0.19%. Short-term trend indicators are bullishly aligned (SMA20 -8.27%, SMA50 -13.38%, SMA200 -29.14%). The stock’s 14-day RSI is 42.13 (neutral), while the ATR of 0.49 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -66.16% below its high and over 130.3% above its low. Average 10-day trading volume of 29.59 thousand shares is below the 3-month average of 56.39 thousand, indicating normal recent market interest.
Earnings & Analyst Outlook
CEL-SCI Corporation generated EPS of -$5.14 over the past year. Five-year average earnings growth is 23.99%. The latest quarter delivered EPS of -$0.09. The next quarter is forecast at $nan. Next year's EPS is expected at -$40.85. CEL-SCI Corporation earnings surprise history is a consistent trend of beating forecasts. The quarter that ended January 13, 2025, missed forecasts by -10.0%. The prior quarter beat by 45.45%. Over the last six quarters, Apple has recorded several small beats. These include 0.0% in May 16, 2024.
Shareholding & Insider Activity
CEL-SCI Corporation has 6.88 million shares outstanding. The public float is 6.32 million shares, elevated short interest at 11.24% of float. This equals 766.46 thousand shares. The short ratio is 2.0 days. Institutional investors hold 6.73% of the float. Insiders own 8.18%. KINSOLVING C RICHARD holds 302.25 thousand shares, DE CLARA MAXIMILIAN has 251.23 thousand shares and PRICHEP PATRICIA B has 232.33 thousand shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.
Financial & Profitability Overview
On valuation metrics, CEL-SCI trades at a P/E of -1.18, P/S of 0.00 and P/B of 2.53. The current ratio is 1.39 and quick ratio is 1.35. Operationally, the company’s inventory turnover is 16.73 and cash conversion cycle is -76.17 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.95, supported by a cash flow-to-debt ratio of -1.60.
Quarterly Financial Highlights
The company ended the quarter with $10.95B in cash and short-term investments, a total debt of $9.38B, and net debt of - $1.57B. Total assets were $28.16B, with equity of $15.96B. Financials further reflected weakness, with operating cash flow of - $17.12B, free cash flow of - $17.16B, and capital expenditures of - $38.11M.
Frequently Asked Questions
What is the current CEL-SCI Corporation (CVM) stock price?
CEL-SCI Corporation (AMEX: CVM) stock price is $3.53 in the last trading session. During the trading session, CVM stock reached the peak price of $3.66 while $3.41 was the lowest point it dropped to. The percentage change in CVM stock occurred in the recent session was 3.22% while the dollar amount for the price change in CVM stock was $0.11.
CVM's industry and sector of operation?
The AMEX listed CVM is part of Biotechnology industry that operates in the broader Healthcare sector. CEL-SCI Corporation designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Who are the executives of CVM?
Dr. Eyal Talor Ph.D.
Chief Scientific Officer
Mr. John Cipriano
Senior Vice President of Regulatory Affairs
Mr. Geert R. Kersten Esq.
Chief Executive & Financial Officer, Treasurer and Director
Dr. Daniel H. Zimmerman Ph.D.
Senior Vice President of Research & Cellular Immunology
Ms. Patricia B. Prichep
Senior Vice President of Operations & Corporation Sec.
Chief Scientific Officer
Mr. John Cipriano
Senior Vice President of Regulatory Affairs
Mr. Geert R. Kersten Esq.
Chief Executive & Financial Officer, Treasurer and Director
Dr. Daniel H. Zimmerman Ph.D.
Senior Vice President of Research & Cellular Immunology
Ms. Patricia B. Prichep
Senior Vice President of Operations & Corporation Sec.
How CVM did perform over past 52-week?
CVM's closing price is 78.28% higher than its 52-week low of $1.98 where as its distance from 52-week high of $13.48 is -73.81%.
How many employees does CVM have?
Number of CVM employees currently stands at 43.
Link for CVM official website?
Official Website of CVM is: https://cel-sci.com
How do I contact CVM?
CVM could be contacted at phone 703 506 9460 and can also be accessed through its website. CVM operates from 8229 Boone Boulevard, Vienna, VA 22182, United States.
How many shares of CVM are traded daily?
CVM stock volume for the day was 29.92K shares. The average number of CVM shares traded daily for last 3 months was 57.5K.
What is the market cap of CVM currently?
The market value of CVM currently stands at $24.26M with its latest stock price at $3.53 and 6.87M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.
© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep